OSL 7.69% 0.7¢ oncosil medical ltd

News: OncoSil Medical completes Fast Track Face-to-Face for CE Mark

  1. The CE Mark is the mandatory regulatory designation required to commercially market and sell the OncoSil™ medical device in the European Union. OncoSil now awaits the final outcome of the review as the Notified Body continues its assessment over the coming weeks.

 
watchlist Created with Sketch. Add OSL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.